Sample2_PDF.pdf
PDF 348 KB Posted
- Solicitation number
- 36C77624R0132
About this file
This document appears to be a quick reference guide for initiating therapy for Parkinson's Disease. It was developed by the Parkinson's Disease Research, Education and Clinical Centers (PADRECCs) and provides guidelines for medication selection and dosing. The guide covers various Parkinson's medications, including Sinemet, Requip, Mirapex, and others, along with starting doses, typical daily doses, and common side effects. It also advises clinicians to assess for impulse control disorder behaviors and monitor for these symptoms during dopamine agonist therapy. The guide serves as a general reference and does not replace clinical judgment or existing practice parameters.
View the file
Other files
| File | Type | Posted |
|---|---|---|
| Amedment 0004 Questions and Answers.xlsx | XLSX spreadsheet | |
| 36C77624R0132 0005.docx | DOCX document | |
| Error Correction List.xlsx | XLSX spreadsheet | |
| Sample1_PPT.pptx | PPTX presentation | |
| 52.212-2 EVALUATION CRITERIA.docx | DOCX document | |
| Sample3_Interactive_PDF.pdf | ||
| 36C77624R0132 0004_1.docx | DOCX document | |
| PWS_508 REMEDIATION SERVICES -Sept2024.docx | DOCX document | |
| 52.212-1 ADDENDUM to FAR 52.212-1.docx | DOCX document | |
| SectionBCLINs.xlsx | XLSX spreadsheet | |
| Purpose of Amendment.docx | DOCX document | |
| 36C77624R0132 0003_1.docx | DOCX document | |
| 36C77624R0132 0002.docx | DOCX document | |
| 36C77624R0132 0001_1.docx | DOCX document | |
| 36C77624R0132_1.docx | DOCX document |
Show all 15
On GovTribe
Work with this file
- Download the original file
- Contacts named in this file
- Similar government files
- Ask GovTribe AI about this file
Text version
Parkinson’s Disease Quick Reference Guide for Initiating Therapy
The movement disorder experts from the 6 PADRECCs developed the following algorithm to be used as a general guideline, and is not intended to interfere with clinical judgment or replace existing practice parameters.
* Assess for history of Impulse Control Disorder—type behaviors (pathological gambling, eating, spending, sexual, etc) and consider using other agents if significant history and/or concerns exist; monitor for ICD symptoms periodically during dopamine agonist therapy
Please contact one of the six Parkinson’s Disease Research, Education and Clinical Centers (PADRECCs) for additional information or to arrange a consult appointment.
PADRECC/Consortium Hotline: 1-800-949-1001 x5769 Houston PADRECC: 713-794-7841 Philadelphia PADRECC: 215-823-5934 or 888-959-2323 Portland / Seattle PADRECC: 503-721-1091 or 206-277-4560 Richmond PADRECC: 804-675-5931 or 800-784-8381 x5931 San Francisco PADRECC: 415-379-5530 West Los Angeles PADRECC: 310-478-3711 x48001 www.parkinsons.va.gov
Employee Education System Updated May 2019 https://www.parkinsons.va.gov/
Medications Used to Treat Parkinson’s Disease
Medication Name®
(generic name) Start Dose Typical Daily
Dose Common SEs
Sinemet (carbidopa/levodopa)
25/100 1/2 tab TID
25/100 1 tab TID
Sinemet CR (carbidopa/levodopa controlled– release)
25/100 1 tab TID
25/100 or 50/200 1-2 tabs TID
Parcopa (carbidopa/ levodopa orally disin-tegrating tablets)
25/100 1/2 tab TID
25/100 1 tab TID
Comtan (entacapone)
1 (200mg) tab per Sinemet dose
1 (200mg) tab per Sinemet dose
1, urinary discoloration, diarrhea
Stalevo (carbidopa/levodopa/ entacapone)
12.5/50/200 mg TID — or — 25/100/200 mg
TID
25/100/200 mg
TID
Requip (ropinirole HCL)
0.25 mg TID 2.0-5.0 mg TID 1, impulse control disorder (ICD), edema, sedation Mirapex
(pramipexole)
0.125 mg TID 0.5-1.5 mg TID
Neupro (Rotigotine)
2 mg TID 2mg/24 hours 4mg/24 hour
1,2, Application site reaction
Azilect (rasagiline)
0.5 mg daily 1 mg daily 1, 2
Eldepryl (selegiline)
5 mg 5 mg BID 1, 2, psychosis, insomnia
Symmetrel (amantadine)
100 mg daily 100 mg TID pedal edema, psychosis, levido reticularis
Artane (trihexyphenidyl HCL)
1 mg BID 1 mg BID– 2 mg TID
Psychosis, cognitive decline, constipation, urinary retention, dry mouth blurre d vision
Cogentin (benztropine mes ylate)
0.5 mg BID 1-2 mg BID
Side Effect Key 1: Nausea, orthostatic hypotension, dyskinesias, hallucinations, sedation 2: Potential drug interactions with SSRIs (selective serotonin reuptake inhibitors) ICD: Impulse Control Disorder (pathological/impulsive behaviors: gambling, spending, eating, sexual)
File details come from the government source that posted it. Updated .